Healthcare Global Enterprises

    HCG
    Pharma
    ₹599.35
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹8,948 Cr

    P/E
    844.15
    Day range
    ₹570.90 – ₹601.70
    52-week range
    ₹513.30 – ₹775.00
    Volume
    1.79 L
    Open
    ₹570.90
    Prev close
    ₹575.60

    Latest results · Q2 FY27(consolidated)Revenue ₹732 Cr+13.1%Profit ₹9 Cr-55.2%Margin 1.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Factor percentiles

    Value25
    Quality35
    Momentum—
    Low volatility—

    Derived metrics

    Earn. yield
    0.1%
    Graham no.
    ₹75.26
    vs Graham
    -87.4%
    ROE ÷ P/B
    0.3%
    Magic Formula
    #602
    Piotroski
    5/6
    FCF yield
    0.6%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Healthcare Global EnterprisesHCG₹8,948 Cr844.156.352.0%8.0%18.2%1.19+13.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3h ago

    Headlines about Healthcare Global Enterprises from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    225.0
    Price / Book
    6.64
    ROE (FY26)
    2.0%
    ROCE (latest year)
    8%
    Dividend yield
    0.00%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.5%
    Profit 3Y CAGR
    +8.5%
    Revenue YoY (Sep 2026)
    +13.1%
    Profit YoY (Sep 2026)
    -55.2%
    Operating margin
    18.2%
    Net margin
    1.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -200 Cr0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%10%20%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr-250 Cr0 Cr250 Cr500 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-60%-40%-20%0%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x2x4x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales469.87494.63525.58553.54558.57585.16613.16646.85633.07652.33695.10731.80
    Expenses391.26402.60434.68451.30470.19479.53505.37523.54523.51527.25572.84598.41
    Operating Profit78.6192.0390.90102.2488.38105.63107.79123.31109.56125.08122.26133.39
    OPM %16.7%18.6%17.3%18.5%15.8%18.1%17.6%19.1%17.3%19.2%17.6%18.2%
    Other Income6.079.018.8111.135.5410.237.512.93-10.20-18.3213.06-8.68
    Interest29.4626.8433.7135.9840.7044.1745.4743.6244.7842.7039.8738.42
    Depreciation44.1645.9847.0149.7456.5258.0757.9162.8060.6562.8170.4267.80
    Profit before tax11.0628.2218.9927.65-3.3013.6211.9219.82-6.071.2525.0318.49
    Tax %69.0%16.9%28.2%25.2%-334.9%50.3%49.8%-4.2%30.1%-223.2%34.2%50.0%
    Net Profit3.4323.4613.6320.687.756.775.9820.66-7.904.0416.469.25
    EPS in Rs₹0.41₹1.52₹0.86₹1.28₹0.50₹0.52₹0.34₹1.15₹-0.66₹0.15₹0.92₹0.32

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days60

    -7 days since Mar 2021

    Inventory Days32

    0 days since Mar 2021

    Days Payable185

    -36 days since Mar 2021

    Cash Conversion Cycle-93

    +28 days since Mar 2021

    Working Capital Days-61

    -35 days since Mar 2021

    Strengths, risks & growth

    Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 6.64 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Company has low interest coverage ratio.
    • Company has a low return on equity of 4.24% over last 3 years.
    • Promoter holding has decreased over last 3 years: -7.09%

    Compounded Sales Growth

    10 Years
    +16%
    5 Years
    +20%
    3 Years
    +14%
    TTM
    +13%

    Compounded Profit Growth

    10 Years
    +39%
    5 Years
    +18%
    3 Years
    -1%
    TTM
    +12%

    Stock Price CAGR

    10 Years
    +9%
    5 Years
    +19%
    3 Years
    +19%
    1 Year
    -19%

    Return on Equity

    10 Years
    -1%
    5 Years
    +4%
    3 Years
    +4%
    Last Year
    +3%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter63.77%64.21%64.21%64.21%0.00 pp
    FII3.22%2.76%2.73%2.70%-0.03 pp
    DII18.30%18.91%19.20%20.78%+1.58 pp
    Public14.71%14.15%13.86%12.32%-1.54 pp

    Filed with NSE for Sept 2026: promoters 64.21%, public 35.79%

    Analysts & fund holdings

    100%
    100% recommend buy
    9 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E844.2 vs 45.2
    Sector P/B6.05
    Beta0.30

    Who holds the shares, quarter by quarter

    Mutual funds 18.73% (+3.30 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters64.2%
    • Foreign institutions2.7%
    • Mutual funds18.7%
    • Insurance0.9%
    • Other domestic institutions1.2%
    • Retail5.8%
    • Others6.5%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Nippon India Small Cap Fund3.22%0.35%-0.04 pp
    Nippon India ELSS Tax Saver Fund2.56%1.56%-0.11 pp
    Axis Small Cap Fund2.26%0.66%-0.07 pp
    Franklin India Small Cap Fund1.57%1.00%+0.18 pp
    Axis Flexi Cap Fund1.11%0.72%-0.07 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹55 Cr
    FCF yield
    0.6%
    Cash conversion
    15.24
    Accruals ratio
    -0.083
    Net debt
    ₹1,489 Cr
    Net debt / equity
    1.10
    EV / sales
    3.85
    Capex intensity
    11.5%
    Revenue CAGR
    16.1%
    Profit CAGR
    23.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹292 Cr
    8 buys · ₹304 Cr
    12 sells · ₹12.2 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    ASHWINI P KAVADIMATTI
    Designated Person · Pledge Creation
    Pledge5,000₹34.9 L29 Sept 2026
    ASHWINI P KAVADIMATTI
    Designated Person · Market Sale
    Sell500₹3.4 L29 Sept 2026
    Sunu Manuel
    KMP · Pledge Release
    Pledge released38,799₹2.8 Cr14 Aug 2026
    Madan Kumar Sampath
    Designated Person · Invocation of pledge
    Sell34,970₹2.5 Cr12 Aug 2026
    Sunu Manuel
    KMP · Invocation of pledge
    Sell27,000₹1.9 Cr11 Aug 2026
    Bharatsinh S Gadhavi
    Employees/Designated Employees · Market Sale
    Sell13,869₹72.0 L31 Mar 2026
    BHAGYA A AJAIKUMAR
    Promoter Group · Public Right
    Buy105₹53,76031 Mar 2026
    Srinivasa Raghavan
    Employees/Designated Employees · Public Right
    Buy2,132₹10.9 L31 Mar 2026
    AAGNIKA AJAIKUMAR
    Promoter Group · Public Right
    Buy19,250₹98.6 L31 Mar 2026
    CATALYST TRUSTEESHIP LIMITED
    Promoters · Public Right
    Buy14,708₹75.3 L31 Mar 2026
    Hector Asia Holdings II Pte. Ltd.
    Promoters · Public Right
    Buy51,18,036₹262 Cr31 Mar 2026
    ASMITHA AJAIKUMAR
    Promoter Group · Public Right
    Buy19,250₹98.6 L31 Mar 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • rights
      Not available — not reported in this filing

      Rights 1:17 @ Premium Rs 502/-

      2 Mar 2026
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Sept 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Sept 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Sept 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Aug 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2016
      ex-date

    Company announcements

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform you that Healthcare Global (Kenya) Private Limited, a step-down subsidiary of the Company has today, i.e., ....

    Insider Trading / SAST
    Closure of Trading Window

    Intimation regarding closure of Trading Window of the Company for the quarter and half year ending September 30, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer's Report and Voting Results for the agenda(s) listed in the Notice of 28th Annual General Meeting of the Company.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Intimation regarding summary of proceedings of 28th Annual General Meeting of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst/Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure requirements), Regulations 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of meetings with Institutional Investors at Mumbai.

    Company Update
    Intimation Of Grant Of Employee Stock Options Under Healthcare Global Enterprises Limited- Employee Stock Option Scheme, 2026

    The Nomination and Remuneration Committee of the Board of Directors of the Company, at its meeting held today, i.e., September 09, 2026, has approved grant of Employee Stock Options to ....

    Company Update
    Letter To Members Of The Company Containing Weblink And Path Of Integrated Annual Report For The Financial Year 2025-26.

    Please note that letters are being dispatched to the Members of the Company containing web link and path of Integrated Annual Report for Financial Year 2025-26.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper advertisement pertaining to dispatch of 28th Annual General Meeting and Integrated Annual Report for FY 2025-26.

    AGM/EGMPrice-sensitive
    Notice Of 28Th Annual General Meeting Of The Company For FY 2025-26.

    Please find enclosed the Notice of 28th Annual General Meeting and Integrated Annual Report of the Company for FY 2025-26.

    Others
    Reg. 34 (1) Annual Report.

    Please find enclosed the Integrated Annual Report of the Company for FY 2025-26.

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Please find enclosed the Business Responsibility and Sustainability Report ("BRSR") of the Company for FY 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper advertisement pertaining to Notice of Annual General Meeting in accordance with MCA General Circular No. 20/2020 dated May 05, 2020.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Please find attached herewith the Transcript of Earnings Call held on August 07, 2026, with Analysts/Investors to discuss the Unaudited Financial Results (Standalone and Consolidated) of ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, approved at the meeting of Board of Directors held ....

    Filed with BSE (scrip 539787); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Open offer

      HealthCare Global Enterprises Limited

      24 Feb 2025
      Read on SEBI
    • Open offer

      HealthCare Global Enterprises Limited

      5 Jun 2020
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Healthcare Global Enterprises: common questions

    Answered from the figures on this page.

    Healthcare Global Enterprises last traded at ₹599.35 (NSE, as of 18 Nov 2026). The last session moved it up 4.13%.

    Healthcare Global Enterprises is valued at about ₹8,948 crore (NSE, as of 18 Nov 2026).

    Healthcare Global Enterprises trades at a price-to-earnings ratio of 844.15 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Healthcare Global Enterprises has traded between ₹513.30 and ₹775.00 over the past 52 weeks, to 18 Nov 2026. It is currently 33% of the way up that range.

    Healthcare Global Enterprises (HCG) is classified under Pharma on this site's screener.